NEUROCRINE BIOSCIENCES INC (1NBIX.MI) Stock Fundamental Analysis

BIT:1NBIX • US64125C1099

131.55 EUR
+6.15 (+4.9%)
Last: Dec 22, 2025, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

7

1NBIX gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 78 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making 1NBIX a very profitable company, without any liquidiy or solvency issues. 1NBIX has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! With these ratings, 1NBIX could be worth investigating further for value and growth and quality investing!.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year 1NBIX was profitable.
  • 1NBIX had a positive operating cash flow in the past year.
  • In the past 5 years 1NBIX has always been profitable.
  • 1NBIX had a positive operating cash flow in each of the past 5 years.
1NBIX.MI Yearly Net Income VS EBIT VS OCF VS FCF1NBIX.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

  • 1NBIX's Return On Assets of 10.03% is amongst the best of the industry. 1NBIX outperforms 83.95% of its industry peers.
  • 1NBIX has a better Return On Equity (14.25%) than 83.95% of its industry peers.
  • The Return On Invested Capital of 1NBIX (11.10%) is better than 87.65% of its industry peers.
  • 1NBIX had an Average Return On Invested Capital over the past 3 years of 11.40%. This is in line with the industry average of 11.39%.
Industry RankSector Rank
ROA 10.03%
ROE 14.25%
ROIC 11.1%
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
1NBIX.MI Yearly ROA, ROE, ROIC1NBIX.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

  • 1NBIX's Profit Margin of 15.95% is amongst the best of the industry. 1NBIX outperforms 80.25% of its industry peers.
  • 1NBIX's Profit Margin has improved in the last couple of years.
  • 1NBIX's Operating Margin of 20.64% is amongst the best of the industry. 1NBIX outperforms 85.19% of its industry peers.
  • In the last couple of years the Operating Margin of 1NBIX has declined.
  • 1NBIX has a better Gross Margin (98.37%) than 96.30% of its industry peers.
  • 1NBIX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 20.64%
PM (TTM) 15.95%
GM 98.37%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
1NBIX.MI Yearly Profit, Operating, Gross Margins1NBIX.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • 1NBIX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, 1NBIX has more shares outstanding
  • The number of shares outstanding for 1NBIX has been increased compared to 5 years ago.
  • 1NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
1NBIX.MI Yearly Shares Outstanding1NBIX.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
1NBIX.MI Yearly Total Debt VS Total Assets1NBIX.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

  • An Altman-Z score of 8.91 indicates that 1NBIX is not in any danger for bankruptcy at the moment.
  • 1NBIX has a better Altman-Z score (8.91) than 87.65% of its industry peers.
  • There is no outstanding debt for 1NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 8.91
ROIC/WACC1.26
WACC8.78%
1NBIX.MI Yearly LT Debt VS Equity VS FCF1NBIX.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

  • 1NBIX has a Current Ratio of 3.38. This indicates that 1NBIX is financially healthy and has no problem in meeting its short term obligations.
  • 1NBIX's Current ratio of 3.38 is fine compared to the rest of the industry. 1NBIX outperforms 66.67% of its industry peers.
  • 1NBIX has a Quick Ratio of 3.27. This indicates that 1NBIX is financially healthy and has no problem in meeting its short term obligations.
  • 1NBIX's Quick ratio of 3.27 is fine compared to the rest of the industry. 1NBIX outperforms 70.37% of its industry peers.
Industry RankSector Rank
Current Ratio 3.38
Quick Ratio 3.27
1NBIX.MI Yearly Current Assets VS Current Liabilites1NBIX.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 12.06% over the past year.
  • Measured over the past years, 1NBIX shows a very strong growth in Earnings Per Share. The EPS has been growing by 58.39% on average per year.
  • 1NBIX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.61%.
  • The Revenue has been growing by 24.48% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)12.06%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%64.52%
Revenue 1Y (TTM)19.61%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%27.78%

3.2 Future

  • The Earnings Per Share is expected to grow by 35.05% on average over the next years. This is a very strong growth
  • 1NBIX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.42% yearly.
EPS Next Y55.94%
EPS Next 2Y47.98%
EPS Next 3Y37.96%
EPS Next 5Y35.05%
Revenue Next Year21.48%
Revenue Next 2Y19.96%
Revenue Next 3Y16.2%
Revenue Next 5Y12.42%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
1NBIX.MI Yearly Revenue VS Estimates1NBIX.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
1NBIX.MI Yearly EPS VS Estimates1NBIX.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 36.95, the valuation of 1NBIX can be described as expensive.
  • 1NBIX's Price/Earnings ratio is a bit cheaper when compared to the industry. 1NBIX is cheaper than 77.78% of the companies in the same industry.
  • 1NBIX is valuated rather expensively when we compare the Price/Earnings ratio to 27.19, which is the current average of the S&P500 Index.
  • 1NBIX is valuated rather expensively with a Price/Forward Earnings ratio of 21.45.
  • 83.95% of the companies in the same industry are more expensive than 1NBIX, based on the Price/Forward Earnings ratio.
  • 1NBIX's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.06.
Industry RankSector Rank
PE 36.95
Fwd PE 21.45
1NBIX.MI Price Earnings VS Forward Price Earnings1NBIX.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 74.07% of the companies in the same industry are more expensive than 1NBIX, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of 1NBIX indicates a rather cheap valuation: 1NBIX is cheaper than 82.72% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 25.99
EV/EBITDA 23.18
1NBIX.MI Per share data1NBIX.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of 1NBIX may justify a higher PE ratio.
  • 1NBIX's earnings are expected to grow with 37.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.66
PEG (5Y)0.63
EPS Next 2Y47.98%
EPS Next 3Y37.96%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for 1NBIX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NEUROCRINE BIOSCIENCES INC

BIT:1NBIX (12/22/2025, 7:00:00 PM)

131.55

+6.15 (+4.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-28
Earnings (Next)02-04
Inst Owners99.58%
Inst Owner ChangeN/A
Ins Owners1.01%
Ins Owner ChangeN/A
Market Cap13.12B
Revenue(TTM)2.68B
Net Income(TTM)428.00M
Analysts84.57
Price Target155.07 (17.88%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.55%
Min EPS beat(2)7%
Max EPS beat(2)26.1%
EPS beat(4)2
Avg EPS beat(4)-22.42%
Min EPS beat(4)-85.62%
Max EPS beat(4)26.1%
EPS beat(8)3
Avg EPS beat(8)-23.05%
EPS beat(12)4
Avg EPS beat(12)-75.32%
EPS beat(16)4
Avg EPS beat(16)-76.53%
Revenue beat(2)2
Avg Revenue beat(2)3.84%
Min Revenue beat(2)3.28%
Max Revenue beat(2)4.39%
Revenue beat(4)2
Avg Revenue beat(4)1.34%
Min Revenue beat(4)-2.16%
Max Revenue beat(4)4.39%
Revenue beat(8)4
Avg Revenue beat(8)1.12%
Revenue beat(12)6
Avg Revenue beat(12)0.97%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)4.16%
PT rev (3m)N/A
EPS NQ rev (1m)2.56%
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.62%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-0.05%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 36.95
Fwd PE 21.45
P/S 5.75
P/FCF 25.99
P/OCF 24.2
P/B 5.13
P/tB 5.19
EV/EBITDA 23.18
EPS(TTM)3.56
EY2.71%
EPS(NY)6.13
Fwd EY4.66%
FCF(TTM)5.06
FCFY3.85%
OCF(TTM)5.44
OCFY4.13%
SpS22.9
BVpS25.64
TBVpS25.33
PEG (NY)0.66
PEG (5Y)0.63
Graham Number45.32
Profitability
Industry RankSector Rank
ROA 10.03%
ROE 14.25%
ROCE 15.26%
ROIC 11.1%
ROICexc 16.02%
ROICexgc 16.25%
OM 20.64%
PM (TTM) 15.95%
GM 98.37%
FCFM 22.11%
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
ROICexc(3y)30.35%
ROICexc(5y)27.29%
ROICexgc(3y)31.58%
ROICexgc(5y)28.03%
ROCE(3y)15.68%
ROCE(5y)15.92%
ROICexgc growth 3Y35.59%
ROICexgc growth 5Y-0.37%
ROICexc growth 3Y34.3%
ROICexc growth 5Y-0.94%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
F-Score5
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 147.14%
Cap/Sales 1.63%
Interest Coverage 250
Cash Conversion 109.17%
Profit Quality 138.57%
Current Ratio 3.38
Quick Ratio 3.27
Altman-Z 8.91
F-Score5
WACC8.78%
ROIC/WACC1.26
Cap/Depr(3y)126.53%
Cap/Depr(5y)144.2%
Cap/Sales(3y)1.41%
Cap/Sales(5y)1.47%
Profit Quality(3y)172.36%
Profit Quality(5y)166.13%
High Growth Momentum
Growth
EPS 1Y (TTM)12.06%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%64.52%
EPS Next Y55.94%
EPS Next 2Y47.98%
EPS Next 3Y37.96%
EPS Next 5Y35.05%
Revenue 1Y (TTM)19.61%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%27.78%
Revenue Next Year21.48%
Revenue Next 2Y19.96%
Revenue Next 3Y16.2%
Revenue Next 5Y12.42%
EBIT growth 1Y-5.9%
EBIT growth 3Y41.04%
EBIT growth 5Y20.8%
EBIT Next Year4.42%
EBIT Next 3Y19.54%
EBIT Next 5Y19.04%
FCF growth 1Y54.17%
FCF growth 3Y33.71%
FCF growth 5Y32.31%
OCF growth 1Y55.54%
OCF growth 3Y32.41%
OCF growth 5Y31.38%

NEUROCRINE BIOSCIENCES INC / 1NBIX.MI FAQ

Can you provide the ChartMill fundamental rating for NEUROCRINE BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 7 / 10 to 1NBIX.MI.


What is the valuation status for 1NBIX stock?

ChartMill assigns a valuation rating of 6 / 10 to NEUROCRINE BIOSCIENCES INC (1NBIX.MI). This can be considered as Fairly Valued.


How profitable is NEUROCRINE BIOSCIENCES INC (1NBIX.MI) stock?

NEUROCRINE BIOSCIENCES INC (1NBIX.MI) has a profitability rating of 8 / 10.


What is the financial health of NEUROCRINE BIOSCIENCES INC (1NBIX.MI) stock?

The financial health rating of NEUROCRINE BIOSCIENCES INC (1NBIX.MI) is 8 / 10.


What is the expected EPS growth for NEUROCRINE BIOSCIENCES INC (1NBIX.MI) stock?

The Earnings per Share (EPS) of NEUROCRINE BIOSCIENCES INC (1NBIX.MI) is expected to grow by 55.94% in the next year.